Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent

Andrea Sambri, Eric Staals, Manuel Ricardo Medellin, Adesegun Abudu, Panagiotis Gikas, Rob Pollock, Tim Wr Briggs, Davide Maria Donati, Marco Manfrini

Research output: Contribution to journalArticle

Abstract

AIMS: The aim of this study is to assess outcomes of patients ≤12 years who undergo Stanmore noninvasive extendible endoprosthetic replacement of the distal femur (DF NIEPR).

PATIENTS AND METHODS: A total of 101 children (mean age 9.6 years) were included. All complications which required further surgery were recorded. Clinical and functional outcomes were evaluated with Musculoskeletal Tumor Society (MSTS) scores at a mean follow-up of 64 months (range 6-174).

RESULTS: Thirty-one (30.7%) patients died at a mean of 33 months. Forty had prosthesis removed after a mean of 43 months (range, 7-103). Attaining of the full lengthening potential before skeletal maturity was the most frequent reason for revision surgery, particularly in those with smaller lengthening potential (P  =  0.039). Implant survival rate for other causes was 61.7% at 5 years and 45.0% at 10 years. At final follow-up mean MSTS score was 26 (range, 13-29). Twenty-two (21.5%) patients had a final limb-length discrepancy (LLD)  > 2 cm.

CONCLUSIONS: DF NIEPR produces a good functional outcome, with the prevention of major LLD at skeletal maturity in the majority of the cases. We suggest patient selection criteria to account for the stage of the disease due to the high cost of the NIEPR, and high percentage requiring revision, and a 60% mortality rate in those patients presenting with distant disease burden.

Original languageEnglish
JournalJournal of Surgical Oncology
DOIs
Publication statusE-pub ahead of print - May 15 2019

Fingerprint

Sarcoma
Bone and Bones
Patient Selection
Extremities
Therapeutics
Reoperation
Femur
Prostheses and Implants
Neoplasms
Survival Rate
Costs and Cost Analysis
Mortality

Keywords

  • bone tumor
  • distal femur
  • lengthening prosthesis
  • magnetic
  • pediatric tumor

Cite this

Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. / Sambri, Andrea; Staals, Eric; Medellin, Manuel Ricardo; Abudu, Adesegun; Gikas, Panagiotis; Pollock, Rob; Briggs, Tim Wr; Donati, Davide Maria; Manfrini, Marco.

In: Journal of Surgical Oncology, 15.05.2019.

Research output: Contribution to journalArticle

Sambri, Andrea ; Staals, Eric ; Medellin, Manuel Ricardo ; Abudu, Adesegun ; Gikas, Panagiotis ; Pollock, Rob ; Briggs, Tim Wr ; Donati, Davide Maria ; Manfrini, Marco. / Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. In: Journal of Surgical Oncology. 2019.
@article{428c2396cd974190ae17ef034b41ced1,
title = "Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent",
abstract = "AIMS: The aim of this study is to assess outcomes of patients ≤12 years who undergo Stanmore noninvasive extendible endoprosthetic replacement of the distal femur (DF NIEPR).PATIENTS AND METHODS: A total of 101 children (mean age 9.6 years) were included. All complications which required further surgery were recorded. Clinical and functional outcomes were evaluated with Musculoskeletal Tumor Society (MSTS) scores at a mean follow-up of 64 months (range 6-174).RESULTS: Thirty-one (30.7{\%}) patients died at a mean of 33 months. Forty had prosthesis removed after a mean of 43 months (range, 7-103). Attaining of the full lengthening potential before skeletal maturity was the most frequent reason for revision surgery, particularly in those with smaller lengthening potential (P  =  0.039). Implant survival rate for other causes was 61.7{\%} at 5 years and 45.0{\%} at 10 years. At final follow-up mean MSTS score was 26 (range, 13-29). Twenty-two (21.5{\%}) patients had a final limb-length discrepancy (LLD)  > 2 cm.CONCLUSIONS: DF NIEPR produces a good functional outcome, with the prevention of major LLD at skeletal maturity in the majority of the cases. We suggest patient selection criteria to account for the stage of the disease due to the high cost of the NIEPR, and high percentage requiring revision, and a 60{\%} mortality rate in those patients presenting with distant disease burden.",
keywords = "bone tumor, distal femur, lengthening prosthesis, magnetic, pediatric tumor",
author = "Andrea Sambri and Eric Staals and Medellin, {Manuel Ricardo} and Adesegun Abudu and Panagiotis Gikas and Rob Pollock and Briggs, {Tim Wr} and Donati, {Davide Maria} and Marco Manfrini",
note = "{\circledC} 2019 Wiley Periodicals, Inc.",
year = "2019",
month = "5",
day = "15",
doi = "10.1002/jso.25501",
language = "English",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent

AU - Sambri, Andrea

AU - Staals, Eric

AU - Medellin, Manuel Ricardo

AU - Abudu, Adesegun

AU - Gikas, Panagiotis

AU - Pollock, Rob

AU - Briggs, Tim Wr

AU - Donati, Davide Maria

AU - Manfrini, Marco

N1 - © 2019 Wiley Periodicals, Inc.

PY - 2019/5/15

Y1 - 2019/5/15

N2 - AIMS: The aim of this study is to assess outcomes of patients ≤12 years who undergo Stanmore noninvasive extendible endoprosthetic replacement of the distal femur (DF NIEPR).PATIENTS AND METHODS: A total of 101 children (mean age 9.6 years) were included. All complications which required further surgery were recorded. Clinical and functional outcomes were evaluated with Musculoskeletal Tumor Society (MSTS) scores at a mean follow-up of 64 months (range 6-174).RESULTS: Thirty-one (30.7%) patients died at a mean of 33 months. Forty had prosthesis removed after a mean of 43 months (range, 7-103). Attaining of the full lengthening potential before skeletal maturity was the most frequent reason for revision surgery, particularly in those with smaller lengthening potential (P  =  0.039). Implant survival rate for other causes was 61.7% at 5 years and 45.0% at 10 years. At final follow-up mean MSTS score was 26 (range, 13-29). Twenty-two (21.5%) patients had a final limb-length discrepancy (LLD)  > 2 cm.CONCLUSIONS: DF NIEPR produces a good functional outcome, with the prevention of major LLD at skeletal maturity in the majority of the cases. We suggest patient selection criteria to account for the stage of the disease due to the high cost of the NIEPR, and high percentage requiring revision, and a 60% mortality rate in those patients presenting with distant disease burden.

AB - AIMS: The aim of this study is to assess outcomes of patients ≤12 years who undergo Stanmore noninvasive extendible endoprosthetic replacement of the distal femur (DF NIEPR).PATIENTS AND METHODS: A total of 101 children (mean age 9.6 years) were included. All complications which required further surgery were recorded. Clinical and functional outcomes were evaluated with Musculoskeletal Tumor Society (MSTS) scores at a mean follow-up of 64 months (range 6-174).RESULTS: Thirty-one (30.7%) patients died at a mean of 33 months. Forty had prosthesis removed after a mean of 43 months (range, 7-103). Attaining of the full lengthening potential before skeletal maturity was the most frequent reason for revision surgery, particularly in those with smaller lengthening potential (P  =  0.039). Implant survival rate for other causes was 61.7% at 5 years and 45.0% at 10 years. At final follow-up mean MSTS score was 26 (range, 13-29). Twenty-two (21.5%) patients had a final limb-length discrepancy (LLD)  > 2 cm.CONCLUSIONS: DF NIEPR produces a good functional outcome, with the prevention of major LLD at skeletal maturity in the majority of the cases. We suggest patient selection criteria to account for the stage of the disease due to the high cost of the NIEPR, and high percentage requiring revision, and a 60% mortality rate in those patients presenting with distant disease burden.

KW - bone tumor

KW - distal femur

KW - lengthening prosthesis

KW - magnetic

KW - pediatric tumor

U2 - 10.1002/jso.25501

DO - 10.1002/jso.25501

M3 - Article

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

ER -